...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinics in dermatology >Current management strategies for cutaneous T-cell lymphoma.
【24h】

Current management strategies for cutaneous T-cell lymphoma.

机译：皮肤T细胞淋巴瘤的当前治疗策略。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cutaneous T-Cell Lymphoma is a group of lymphomas characterized by a malignant proliferation of skin homing T cells. Prognosis is generally good and treatment is based on the stage of the disease with the goal of inducing remission. Patients with disease limited to the skin in the form of patches and plaques respond best to "skin directed therapy" with topical agents including corticosteroids, nitrogen mustard, carmustine, bexarotene gel, as well as phototherapy with ultraviolet B light, PUVA, or photodynamic therapy. Tazarotene and imiquimod show potential in the treatment of early CTCL. Patients with disease resistant to treatment or with advanced disease require more aggressive therapy in the form of total skin electron beam radiation, biologic response modifiers including interferon alpha, bexarotene, denileukin diftitox, extracorporeal photochemotherapy or combination therapy. The use of chemotherapy is used primarily for palliation. Allogeneic hematopoetic stem cell transplantation may represent a successful treatment for treatment resistant disease.
机译：皮肤T细胞淋巴瘤是一组以归巢性T细胞恶性增殖为特征的淋巴瘤。预后一般良好，治疗以疾病的分期为基础，以诱导缓解为目标。以斑块和斑块形式局限于皮肤的疾病患者对“皮肤定向疗法”的反应最佳，包括皮质类固醇，氮芥子气，卡莫司汀，贝沙罗汀凝胶等局部用药，以及紫外线B光，PUVA或光动力疗法的光疗。他扎罗汀和咪喹莫特在早期CTCL的治疗中显示出潜力。对治疗有抵抗力或患有晚期疾病的患者需要以皮肤电子束总辐射，生物反应调节剂（包括干扰素α，贝沙罗汀，denileukin diftitox，体外光化学疗法或联合疗法）的形式采取更具侵略性的疗法。化疗主要用于缓解疼痛。异基因造血干细胞移植可能代表治疗抗药性疾病的成功方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号